1. Home
  2. SBSI vs ACRS Comparison

SBSI vs ACRS Comparison

Compare SBSI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southside Bancshares Inc.

SBSI

Southside Bancshares Inc.

N/A

Current Price

$32.09

Market Cap

974.1M

Sector

Finance

ML Signal

N/A

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$6.42

Market Cap

868.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBSI
ACRS
Founded
1960
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
974.1M
868.5M
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
SBSI
ACRS
Price
$32.09
$6.42
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$35.33
$10.20
AVG Volume (30 Days)
115.7K
1.9M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
4.42%
N/A
EPS Growth
N/A
69.01
EPS
1.68
N/A
Revenue
N/A
$1,683,000.00
Revenue This Year
$28.87
N/A
Revenue Next Year
$5.82
$4.24
P/E Ratio
$19.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.32
$1.74
52 Week High
$36.20
$6.52

Technical Indicators

Market Signals
Indicator
SBSI
ACRS
Relative Strength Index (RSI) 40.79 63.11
Support Level $31.74 $5.64
Resistance Level $33.37 $6.52
Average True Range (ATR) 0.51 0.29
MACD -0.01 0.03
Stochastic Oscillator 34.77 86.63

Price Performance

Historical Comparison
SBSI
ACRS

About SBSI Southside Bancshares Inc.

Southside Bancshares Inc is a bank holding company. Through its subsidiary, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: